InvestorsHub Logo
Followers 44
Posts 16557
Boards Moderated 0
Alias Born 09/16/2012

Re: CherryTree1 post# 437877

Sunday, 01/23/2022 9:24:04 AM

Sunday, January 23, 2022 9:24:04 AM

Post# of 709414
$$ buys Advisors. ---------------



This is very interesting. Is this Northwest connected to Boynton's old Northwest or new Northwest? LOL. Boynton...No summits, no speeches, no presentations, seems no presence for decades. Lots of older patents, however. All so odd. -----------------------


>>The treatment could extend survival for an estimated 20% to 30% of patients. Currently, patients with glioblastoma do not receive this life-prolonging treatment because it has not been fully understood which of them could benefit.

“This is an important breakthrough for patients who have not had an effective treatment in the cancer drug arsenal available to them,” said Dr. Adam Sonabend, the senior/corresponding author of this study, and associate professor of neurosurgery at Northwestern University Feinberg School of Medicine and a Northwestern Medicine brain-tumor neurosurgeon. “It might ultimately influence the decision on how to treat glioblastoma patients and which patients should get these drugs to prolong their survival.”

https://news.northwestern.edu/stories/2021/11/which-glioblastoma-patients-will-respond-to-immunotherapy/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News